サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がんプロファイリングの世界市場の評価：バイオマーカータイプ別、技術別、がんタイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
市場調査レポート
商品コード
1400696

がんプロファイリングの世界市場の評価：バイオマーカータイプ別、技術別、がんタイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Global Cancer Profiling Market Assessment, By Biomarker Type, By Technology, By Cancer Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 217 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
がんプロファイリングの世界市場の評価：バイオマーカータイプ別、技術別、がんタイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年01月03日
発行: Market Xcel - Markets and Data
ページ情報: 英文 217 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがんプロファイリングの市場規模は、2023年に111億6,000万米ドル、2031年までに225億3,000万米ドルに達し、2024年～2031年の予測期間にCAGRで9.18%の成長が見込まれています。市場は非常にダイナミックであり、多くの市場企業を育んでいます。世界中でがん患者が増加していることから、市場は飛躍的な成長が見込まれています。

WHOによると、がんは世界的に死因の第2位となっています。がんの有病率の急増は、遺伝子突然変異、アルコールとタバコの消費、ホルモンとライフスタイルの変化、発がん性微生物感染に起因すると考えられ、これらは世界のがんプロファイリング市場を牽引する重要な役割を果たしています。この事実を受け、医療従事者や市場参入企業は、がんの負担を軽減する正確ながん診断に向けたがんプロファイリングのような、より先進のソリューションの開発に注力しています。

腫瘍プロファイリングは、医療従事者が個人のユニークな遺伝子プロファイルに基づいて個別化治療を開発することを可能にし、非常に効果的な治療成果につながります。がんプロファイリング市場は、がんの診断や予測にAIや機械学習などの技術を利用することで拡大しています。

がんの有病率の増加

がんは、先進国でも発展途上国でも主な死因の1つとなっています。放射線被曝、アルコールやタバコの摂取、ライフスタイルの変化が、世界のがん患者数の増加の主な原因となっています。がんのプロファイリングと治療に使用できる精密診断の開発により、がんプロファイリング市場の成長が予測されています。この場合、がんプロファイリングはカスタマイズされた代替の治療法の提供に不可欠であり、これが世界のがんプロファイリング市場の成長をさらに促進します。WHOによると、新たにがんと診断される症例は2025年までに12.1%の成長率で約2,162万人に増加すると予測されています。すべての症例の中で、乳がんは世界でもっとも罹患率の高いがんです。乳がんはすべてのがんの中で第1位で、12％のシェアを占めています。

個別化治療への選好の高まり

がん治療における治療成果の向上は、個別化治療によって達成される可能性があります。腫瘍やがんのプロファイリングは個別化治療開発の準備段階であり、これが市場の革新と成長を後押ししています。ゲノム技術の進歩に導かれたこの個別化アプローチは、治療効果を高め、副作用を軽減し、患者の転帰を改善します。臨床試験デザインにおけるがんプロファイリングの統合、免疫療法の人気の高まり、政府の支持的な取り組みなどが、がん治療における個別化医療の採用拡大に寄与しています。

政府の取り組み

世界中の政府は、啓発キャンペーンを通じてがんの検診と治療を積極的に推進しており、このことが世界のがんプロファイリング市場の成長を促進しています。政府はがん診断技術を対象とした研究プロジェクトに資金を提供しています。2023年3月、米国政府は3億9,450万米ドルをCDCの3つのプログラム、National Comprehensive Cancer Control Program、National Breast and Cervical Cancer Early Detection Programs、Colorectal Cancer Control Programに投資し、同国のがん負担を軽減しました。2023年1月、英国では乳がんの罹患率を減少させるため、政府が29の乳がん検診施設の新設に1,000万ユーロを投資すると発表しました。

COVID-19の影響

COVID-19パンデミックは世界のがんプロファイリング市場に大きな影響を与えました。がん患者はもっとも脆弱な集団の1つでした。がん検診はがんの抑制と予防に不可欠ですが、COVID-19パンデミックの結果、多数の検診が中止または延期され、必要なケアの受診に対し多くの患者が影響を受けました。COVID-19によるがんプロファイリング市場の混乱は、患者、医療従事者、医療システムに大規模な影響を与えました。2022年6月にSAGEに掲載された論文によると、2019年～2020年に乳がん検診のマンモグラフィは44%減少しました。

当レポートでは、世界のがんプロファイリング市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界のがんプロファイリング市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界のがんプロファイリング市場の見通し（2017年～2031年）

  • 市場規模と予測
    • 金額
    • 数量
  • バイオマーカータイプ別
    • 遺伝的バイオマーカー
    • タンパク質バイオマーカー
    • その他のがんバイオマーカー
  • 技術別
    • 免疫学的検査
    • 次世代シーケンシング（NGS）
    • ポリメラーゼ連鎖反応（PCR）
    • In Situハイブリダイゼーション（ISH）
    • マイクロアレイ
    • 分光法
    • その他
  • がんタイプ別
    • 乳がん
    • 肺がん
    • 大腸がん
    • 黒色腫
    • 血液がん
    • 前立腺がん
    • 卵巣がん
    • 胃がん
    • 肝臓がん
    • その他のがん
  • 用途別
    • 臨床用途
    • 研究用途
  • エンドユーザー別
    • 病院内診断研究所
    • 診断センター
    • がん研究機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場シェア：企業別（2022年）

第7章 世界のがんプロファイリング市場の見通し（2017年～2031年）

  • 北米
    • 市場規模と予測
    • バイオマーカータイプ別
    • 技術別
    • がんタイプ別
    • 用途別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第8章 市場マッピング（2023年）

  • バイオマーカータイプ別
  • 技術別
  • がんタイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第9章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析 - 数量と金額
  • サプライ/バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第10章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第11章 規制枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第12章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2023年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社向け）
  • 特許分析（該当する場合）

第13章 価格分析

第14章 ケーススタディ

第15章 主要企業の見通し

  • Illumina, Inc.
  • QIAGEN NV
  • NeoGenomics Laboratories, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Genomic Health Inc.
  • Caris Life Sciences
  • Helomics Corporation
  • NanoString Technologies, Inc.
  • Sysmex Corporation
  • Ribomed Biotechnologies, Inc.
  • Guardant Health, Inc.
  • Foundation Medicine
  • Roche Holding AG
  • GenScript Biotech Corporation
  • Tempus Labs, Inc.

第16章 戦略的推奨事項

第17章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 4. Global Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 5. Global Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 6. Global Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Cancer Profiling Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 11. North America Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 12. North America Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 13. North America Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 14. North America Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 15. North America Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 19. United States Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 20. United States Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 21. United States Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. United States Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 23. United States Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 26. Canada Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 27. Canada Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 28. Canada Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 29. Canada Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 33. Mexico Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 34. Mexico Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 35. Mexico Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 36. Mexico Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 37. Mexico Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 40. Europe Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 41. Europe Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 42. Europe Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. Europe Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 44. Europe Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. Germany Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 49. Germany Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 50. Germany Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 51. Germany Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 52. Germany Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 55. France Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 56. France Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 57. France Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. France Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 59. France Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 62. Italy Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 63. Italy Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 64. Italy Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 65. Italy Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 66. Italy Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 69. United Kingdom Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 70. United Kingdom Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 71. United Kingdom Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 72. United Kingdom Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 73. United Kingdom Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 76. Russia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 77. Russia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 78. Russia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 79. Russia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 80. Russia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 83. Netherlands Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 84. Netherlands Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 85. Netherlands Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 86. Netherlands Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 87. Netherlands Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Spain Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 91. Spain Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 92. Spain Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 93. Spain Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 94. Spain Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 97. Turkey Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 98. Turkey Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 99. Turkey Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 100. Turkey Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 101. Turkey Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 104. Poland Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 105. Poland Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 106. Poland Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 107. Poland Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 108. Poland Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 111. South America Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 112. South America Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 113. South America Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 114. South America Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 115. South America Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 119. Brazil Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 120. Brazil Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 121. Brazil Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 122. Brazil Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 123. Brazil Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 126. Argentina Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 127. Argentina Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 128. Argentina Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 129. Argentina Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 130. Argentina Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 133. Asia-Pacific Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 134. Asia-Pacific Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 135. Asia-Pacific Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 136. Asia-Pacific Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 137. Asia- Pacific Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 139. India Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 141. India Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 142. India Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 143. India Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 144. India Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 145. India Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 148. China Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 149. China Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 150. China Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. China Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 152. China Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 155. Japan Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 156. Japan Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 157. Japan Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 158. Japan Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 159. Japan Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 162. Australia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 163. Australia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 164. Australia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 165. Australia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 166. Australia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 169. Vietnam Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 170. Vietnam Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 171. Vietnam Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 172. Vietnam Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 173. Vietnam Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 176. South Korea Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 177. South Korea Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 178. South Korea Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 179. South Korea Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 180. South Korea Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. Indonesia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 184. Indonesia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 185. Indonesia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 186. Indonesia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 187. Indonesia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 190. Philippines Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 191. Philippines Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 192. Philippines Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 193. Philippines Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 194. Philippines Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 197. Middle East & Africa Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 198. Middle East & Africa Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 199. Middle East & Africa Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 200. Middle East & Africa Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 201. Middle East & Africa Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Cancer Profiling Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 205. Saudi Arabia Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 206. Saudi Arabia Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 207. Saudi Arabia Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 208. Saudi Arabia Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 209. Saudi Arabia Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 212. UAE Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 213. UAE Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 214. UAE Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 215. UAE Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 216. UAE Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Cancer Profiling Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Cancer Profiling Market, By Volume, In Million Units, 2017-2031F
  • Figure 219. South Africa Cancer Profiling Market Share (%), By Biomarker Type, 2017-2031F
  • Figure 220. South Africa Cancer Profiling Market Share (%), By Technology, 2017-2031F
  • Figure 221. South Africa Cancer Profiling Market Share (%), By Cancer Type, 2017-2031F
  • Figure 222. South Africa Cancer Profiling Market Share (%), By Application, 2017-2031F
  • Figure 223. South Africa Cancer Profiling Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Biomarker Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX10781

Global cancer profiling market size was valued at USD 11.16 billion in 2023, expected to reach USD 22.53 billion in 2031, with a CAGR of 9.18% for the forecast period between 2024 and 2031F. The global cancer profiling market is highly dynamic, fostering many market players. The market is expected to grow exponentially due to the increasing number of cancer cases around the world.

As per WHO, cancer is the second leading cause of death globally. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, and carcinogenic microbial infections, which play an important role in driving the global cancer profiling market. Owing to this fact, healthcare professionals and market players are focused on developing more advanced solutions like cancer profiling for precise cancer diagnosis to reduce the cancer burden.

Tumor profiling enables healthcare professionals to develop personalized therapy based on unique genetic profiles of individuals, leading to highly effective therapeutic outcomes. The market for cancer profiling is expanding due to the use of technology such as artificial intelligence and machine learning for cancer diagnosis and prediction.

Growing industry partnerships, the introduction of cutting-edge products, and government programs to promote cancer screening are expected to fuel market expansion throughout the projected period. In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men.

Increasing Prevalence of Cancer

Cancer is one of the leading causes of death in developed and developing countries. Exposure to radiation, alcohol and tobacco consumption, and lifestyle changes are the major contributors to the increasing number of cancer patients globally. The market for cancer profiling is expected to grow due to the development of precise diagnostics that can be used to profile and treat cancer. In this case, cancer profiling becomes essential for offering customized treatment alternatives, which further propels the growth of global cancer profiling market. As per WHO, newly diagnosed cancer cases are expected to increase to around 21.62 million with a growth rate of 12.1% by 2025. Among all cases, breast cancer is the world's most prevalent cancer. Breast cancer ranks first among all types of cancer accounting for 12% share.

Growing Preference to Personalized Therapies

Improved outcomes in cancer treatments can be achieved by personalized therapy. Tumor or cancer profiling is the preliminary step in the development of personalized therapy, which drives innovation and growth in the market. This personalized approach, guided by advancements in genomic technologies, increases treatment efficacy, reduces adverse effects, and improves patient outcomes. The integration of cancer profiling in clinical trial design, increasing popularity of immunotherapy, and supportive government initiatives contribute to the growing adoption of personalized medicine in cancer care.

In March 2023, Artera invested USD 90 million to customize treatment for prostate cancer. The business will use the money to distribute its ArteraAI Prostate Test and create tests that would enable customized treatment plans for various cancers. By examining the patient's clinical information and biopsy images, Artera's multimodal AI-powered test for prostate cancer patients, known as the ArteraAI Prostate Test, assists in forecasting the possible advantages of treatment and the patient's prognosis.

Government Initiatives

Governments around the globe are actively pushing cancer screening and therapies through awareness campaigns, which is driving growth in the worldwide cancer profiling market. The government is funding research projects targeting cancer diagnosis techniques. In March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and the Colorectal Cancer Control Program to reduce the cancer burden of the country. In January 2023, to decrease the incidence of breast cancer in the United Kingdom, government announced investment of EUR 10 million to build 29 new breast cancer screening facilities.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the global cancer profiling market. Cancer patients were amongst the most vulnerable populations. Although cancer screening is essential for controlling and prevention of cancer, a large number of screenings were canceled or postponed as a result of the COVID-19 pandemic, affecting a large number of patients for access to necessary medical care. There was large scale impact on patients, medical professionals, and health system from the disruption caused by COVID-19 on cancer profiling market. According to a paper published in SAGE in June 2022, between 2019 and 2020, there was a 44% decrease in breast cancer screening mammography.

Key Players Landscape and Outlook

Market players are employing a range of strategies to increase their range of solutions offered while giving their customers access to a wide selection of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic services they offer to capture a large portion of the market. Many major industry players are using both organic and inorganic growth techniques, like partnerships, mergers and acquisitions, and launch of new products, to strengthen their position in the global market.

In April 2023, Agilent Technologies introduced a CGP test intended for somatic variant profiling. The technique, known as Agilent SureSelect Cancer CGP, decreases hands-on time and increases workflow efficiency to enable scientists to profile a larger variety of tumor samples. The pan-cancer test was developed based on a next-generation sequencing (NGS) panel of 679 genes compiled from cancer databases and research collaborations.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Cancer Profiling Market

4. Executive Summary

5. Global Cancer Profiling Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Biomarker Type
    • 5.2.1 Genetic Biomarkers
    • 5.2.2 Protein Biomarkers
    • 5.2.3 Other Cancer Biomarkers
  • 5.3 By Technology
    • 5.3.1 Immunoassays
    • 5.3.2 Next-generation Sequencing (NGS)
    • 5.3.3 Polymerase Chain Reaction (PCR)
    • 5.3.4 In Situ Hybridization (ISH)
    • 5.3.5 Microarrays
    • 5.3.6 Spectroscopic Method
    • 5.3.7 Others
  • 5.4 By Cancer Type
    • 5.4.1 Breast Cancer
    • 5.4.2 Lung Cancer
    • 5.4.3 Colorectal Cancer
    • 5.4.4 Melanoma
    • 5.4.5 Blood Cancer
    • 5.4.6 Prostate Cancer
    • 5.4.7 Ovarian Cancer
    • 5.4.8 Stomach Cancer
    • 5.4.9 Liver Cancer
    • 5.4.10 Other Cancer
  • 5.5 By Application
    • 5.5.1 Clinical Application
      • 5.5.1.1 Diagnostics
      • 5.5.1.2 Prognostics
      • 5.5.1.3 Monitoring and Treatment
      • 5.5.1.4 Screening
    • 5.5.2 Research Application
      • 5.5.2.1 Biomarker Discovery
      • 5.5.2.2 Drug Development
  • 5.6 By End-user
    • 5.6.1 Hospital Associated Diagnostic Laboratories
    • 5.6.2 Diagnostic Centers
    • 5.6.3 Cancer Research Institutes
    • 5.6.4 Others
  • 5.7 By Region
    • 5.7.1 North America
    • 5.7.2 Europe
    • 5.7.3 Asia-Pacific
    • 5.7.4 South America
    • 5.7.5 Middle East & Africa
  • 5.8 By Company Market Share (%), 2022

7. Global Cancer Profiling Market Outlook, 2017-2031F

  • 7.1. North America
    • 7.1.1. Market Size & Forecast
      • 7.1.1.1. By Value
      • 7.1.1.2. By Volume
    • 7.1.2. By Biomarker Type
      • 7.1.2.1. Genetic Biomarkers
      • 7.1.2.2. Protein Biomarkers
      • 7.1.2.3. Other Cancer Biomarkers
    • 7.1.3. By Technology
      • 7.1.2.1 Immunoassays
      • 7.1.2.2 Next-generation Sequencing (NGS)
      • 7.1.2.3 Polymerase Chain Reaction (PCR)
      • 7.1.2.4 In Situ Hybridization (ISH)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Spectroscopic Method
      • 7.1.2.7 Others
    • 7.1.3 By Cancer Type
      • 7.1.3.1 Breast Cancer
      • 7.1.3.2 Lung Cancer
      • 7.1.3.3 Colorectal Cancer
      • 7.1.3.4 Melanoma
      • 7.1.3.5 Blood Cancer
      • 7.1.3.6 Prostate Cancer
      • 7.1.3.7 Ovarian Cancer
      • 7.1.3.8 Stomach Cancer
      • 7.1.3.9 Liver Cancer
      • 7.1.3.10 Other Cancer
    • 7.1.4 By Application
      • 7.1.4.1 Clinical Application
      • 7.1.4.1.1 Diagnostics
      • 7.1.4.1.2 Prognostics
      • 7.1.4.1.3 Monitoring and Treatment
      • 7.1.4.1.4 Screening
      • 7.1.4.2 Research Application
      • 7.1.4.2.1 Biomarker Discovery
      • 7.1.4.2.2 Drug Development
    • 7.1.4. By End-user
      • 7.1.4.1. Hospital Associated Diagnostic Laboratories
      • 7.1.4.2. Diagnostic Centers
      • 7.1.4.3. Cancer Research Institutes
      • 7.1.4.4. Others
    • 7.1.5. United States*
      • 7.1.5.1. Market Size & Forecast
      • 7.1.5.1.1. By Value
      • 7.1.5.1.2. By Volume
      • 7.1.4.1 By Biomarker Type
      • 7.1.5.1.3. Genetic Biomarkers
      • 7.1.5.1.4. Protein Biomarkers
      • 7.1.5.1.5. Other Cancer Biomarkers
      • 7.1.5.2. By Technology
      • 7.1.4.2.1 Immunoassays
      • 7.1.4.2.2 Next-generation Sequencing (NGS)
      • 7.1.4.2.3 Polymerase Chain Reaction (PCR)
      • 7.1.4.2.4 In Situ Hybridization (ISH)
      • 7.1.4.2.5 Microarrays
      • 7.1.4.2.6 Spectroscopic Method
      • 7.1.4.2.7 Others
      • 7.1.4.3 By Cancer Type
      • 7.1.4.3.1 Breast Cancer
      • 7.1.4.3.2 Lung Cancer
      • 7.1.4.3.3 Colorectal Cancer
      • 7.1.4.3.4 Melanoma
      • 7.1.4.3.5 Blood Cancer
      • 7.1.4.3.6 Prostate Cancer
      • 7.1.4.3.7 Ovarian Cancer
      • 7.1.4.3.8 Stomach Cancer
      • 7.1.4.3.9 Liver Cancer
      • 7.1.4.3.10 Other Cancer
      • 7.1.4.4 By Application
      • 7.1.4.4.1 Clinical Application
      • 7.1.4.4.1.1 Diagnostics
      • 7.1.4.4.1.2 Prognostics
      • 7.1.4.4.1.3 Monitoring and Treatment
      • 7.1.4.4.1.4 Screening
      • 7.1.4.4.2 Research Application
      • 7.1.4.4.2.1 Biomarker Discovery
      • 7.1.4.4.2.2 Drug Development
      • 7.1.4.5 By End-user
      • 7.1.4.5.1 Hospital Associated Diagnostic Laboratories
      • 7.1.4.5.2 Diagnostic Centers
      • 7.1.4.5.3 Cancer Research Institutes
      • 7.1.4.5.4 Others
    • 7.1.5 Canada
    • 7.1.6 Mexico

All segments will be provided for all regions and countries covered

  • 7.2 Europe
    • 7.2.2 Germany
    • 7.2.3 France
    • 7.2.4 Italy
    • 7.2.5 United Kingdom
    • 7.2.6 Russia
    • 7.2.7 Netherlands
    • 7.2.8 Spain
    • 7.2.9 Turkey
    • 7.2.10 Poland
  • 7.3 South America
    • 7.3.2 Brazil
    • 7.3.3 Argentina
  • 7.4 Asia-Pacific
    • 7.4.2 India
    • 7.4.3 China
    • 7.4.4 Japan
    • 7.4.5 Australia
    • 7.4.6 Vietnam
    • 7.4.7 South Korea
    • 7.4.8 Indonesia
    • 7.4.9 Philippines
  • 7.5 Middle East and Africa
    • 7.5.2 Saudi Arabia
    • 7.5.3 UAE
    • 7.5.4 South Africa

8 Market Mapping, 2023

  • 8.1 By Biomarker Type
  • 8.2 By Technology
  • 8.3 By Cancer Type
  • 8.4 By Application
  • 8.5 By End-user
  • 8.6 By Region

9 Macro Environment and Industry Structure

  • 9.1 Supply Demand Analysis
  • 9.2 Import Export Analysis - Volume and Value
  • 9.3 Supply/Value Chain Analysis
  • 9.4 PESTEL Analysis
    • 9.4.2 Political Factors
    • 9.4.3 Economic System
    • 9.4.4 Social Implications
    • 9.4.5 Technological Advancements
    • 9.4.6 Environmental Impacts
    • 9.4.7 Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 9.5 Porter's Five Forces Analysis
    • 9.5.2 Supplier Power
    • 9.5.3 Buyer Power
    • 9.5.4 Substitution Threat
    • 9.5.5 Threat from New Entrant
    • 9.5.6 Competitive Rivalry

10 Market Dynamics

  • 10.1 Growth Drivers
  • 10.2 Growth Inhibitors (Challenges, Restraints)

11 Regulatory Framework and Innovation

  • 11.1 Clinical Trials
  • 11.2 Patent Landscape
  • 11.3 Regulatory Approvals
  • 11.4 Innovations/Emerging Technologies

12 Key Players Landscape

  • 12.1 Competition Matrix of Top Five Market Leaders
  • 12.2 Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 12.3 Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 12.4 SWOT Analysis (For Five Market Players)
  • 12.5 Patent Analysis (If Applicable)

13 Pricing Analysis

14 Case Studies

15 Key Players Outlook

  • 15.1 Illumina, Inc.
    • 15.1.2 Company Details
    • 15.1.3 Key Management Personnel
    • 15.1.4 Products & Services
    • 15.1.5 Financials (As reported)
    • 15.1.6 Key Market Focus & Geographical Presence
    • 15.1.7 Recent Developments
  • 15.2 QIAGEN NV
  • 15.3 NeoGenomics Laboratories, Inc.
  • 15.4 HTG Molecular Diagnostics, Inc.
  • 15.5 Genomic Health Inc.
  • 15.6 Caris Life Sciences
  • 15.7 Helomics Corporation
  • 15.8 NanoString Technologies, Inc.
  • 15.9 Sysmex Corporation
  • 15.10 Ribomed Biotechnologies, Inc.
  • 15.11 Guardant Health, Inc.
  • 15.12 Foundation Medicine
  • 15.13 Roche Holding AG
  • 15.14 GenScript Biotech Corporation
  • 15.15 Tempus Labs, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

16 Strategic Recommendations

17 About Us & Disclaimer